Accurate staging of lung cancer is essential for proper treatment and management of the disease, and allows predictions for patient survival. Several different invasive and noninvasive modalities exist for staging, and the determination of the best approach of one or a combination of those methods depends on the clinical situation and the clinician's assessment of the most appropriate means of staging evaluation. This review discusses the elements and framework of lung cancer staging, with particular emphasis on those newer modalities, especially positron emission tomography and endoscopic ultrasound needle biopsy, which will be expected to be used increasingly more common in clinical practice.
After an anatomical pathologic diagnosis of bronchogenic carcinoma has been made, the next consideration is to determine the extent of disease, or stage, because this will direct appropriate therapy and predict survival. The most significant treatment decision is between those patients who can benefit from surgical resection of their neoplasm or those who should receive chemotherapy or radiation or both. Staging in regards to a patient's potential for surgical resection is most applicable to non-small cell lung cancer, because surgical therapy is not a treatment alternative for small cell carcinoma; rather, for small cell cancer a more simplified staging classification of limited and extensive disease is utilized. The implication in small cell cancer is that limited disease is treated with chemotherapy and radiation, and extensive disease with chemotherapy alone. For non-small cell lung cancer, the TMN staging system is employed with TMN subsets grouped into clinical stages (see Tables 1  and 2) [3, 4] .
This article reviews recent developments in the staging of lung cancer, especially within the last year. Major recent issues in the literature focus on which of the diagnostic modalities is most useful and accurate for each segment of the TMN classification system, with particular attention to the role of positron emission tomography (PET) scanning for evaluation of the mediastinum, and the exciting development of endoscopic ultrasound guided lymph node biopsy. The last major revision of the stage-grouping framework occurred in 1997, but refinements in the staging system are an ongoing process. In addition, further application of the lung cancer staging system in the form of practice guidelines are promulgated and updated frequently.
T (Tumor) Status Assessment
Establishing the T status of a neoplasm depends on the size and location of the tumor. Most lung cancers are initially detected by plain chest radiograph, which provide a reasonably accurate determination of tumor size, and in some cases mediastinal staging can be accomplished as well in those cases of bulky lymphadenopathy in the superior or contralateral mediastinal areas. For practical purposes, however, chest computed tomography is the modern standard of care for initial assessment of tumor size and mediastinal involvement, and practice guidelines uniformly support this recommendation.. The technical fact of the marked difference in attenuation between aerated lung parenchyma and neoplastic tissue makes CT the preferred imaging modality for assessing tumor size and location, whereas some degree of magnification is caused by plain chest radiographs owing to the scatter of x-ray beams. CT of the thorax is not error-proof and a word of caution is warranted, because the ultimate difference between T3 and T4 lesions is the achievement of surgical resection, which may be precluded by tumor invasion of mediastinum, heart, great vessels, trachea, esophagus, or carina. Equivocal chest wall involvement on CT may not allow for definite classification between T2 and T3 status. In both cases, the final arbiter of T status is that which is discovered at the time of thoracotomy, and this potential for discrepancy was illustrated by a report of the sensitivity, specificity, and accuracy of CT for T status assessment in such cases were 52%, 86%, and 71% respectively [5] .
N (Nodal) Status Assessment
Literature from the last decade demonstrated conclusively that chest CT as a sole means of staging the mediastium is not sufficiently reliable. Mediastinal lymph nodes with a short axis diameter of greater than 1.0 cm are considered abnormal by widespread convention [6-9] and yield an overall accuracy of approximately 70%. In other words, even in the face of a known lung cancer, an enlarged mediastinal lymph node will not be malignant 30% of the time. In one series of patients evaluated by CT, with results compared to the gold standard of mediastinoscopy, sensitivity and specificity of CT regarding hilar and mediastinal lymph node staging were 48.3 and 53.3%, positive and negative predicative value 40 and 61.1% and its overall accuracy 51.4%, but a more broad review of the literature reveals an accuracy of approximately 70% [10]. It appears that chest CT can be made safer for patients by eliminating the injection of contrast material on a routine basis for the evaluation of mediastinal adenopathy or extrathoracic disease, since this does not improve the accuracy of the CT [11, 12] .
Leaving for a moment the discussion of PET scanning for assessing disease involvement of the mediastium, several diagnostic modalities exist for obtaining tissue for histologic diagnosis. Recent literature reports refinements in these techniques and discusses their relative merits compared to other modalities. The range of options for acquiring lymph node tissue for examination include: CT guided transthoracic needle biopsy, trans- Table 1 . TNM definitions TX Tumor proven by the presence of malignant cells in bronchopulmonary sevreation but not visualized roentgenographically or bronchoscopically, or any tumor that cannot be assessed, as in a retreatment staging. T0 No evidence of primary tumor. TIS Carcinoma in situ. T1 A tumor that 3.0 cm or less in greatest dimension, surrounded by lung or visceral pleura, and without evidence of invasion proximal to a lobar bronchus at bronchoscopy.* T2 A tumor more that 3.0 cm in greatest dimension, or a tumor of any size that either invades the visceral pleura or has associated atelectasis or obstructive pneumonitis extending to the hilar region. At bronchoscopy, the proximal extent of demonstrable tumor must be within a lobar bronchus or at least 2.0 cm distal to the carina. Any associated atelectasis or obstructive pneumonitis must involve less than an entire lung. T3 A tumor of any size with direct extension into the chest wall (including superior sulcus tumors), diagphragm, or the mediastinal pleura or pericardium without involving the heart, great vessels, trachea, esophagus or vertebral body, or a tumor in the main bronchus within 2 cm of the carina without involving the carina, or associated atelectasis or obstructive pneumonitis of entire lung. T4 A tumor of any size with invasiohn of the mediastinum or involving heart, great vessels, tachea, esophagus, vertebral body, or carina or presence of malignant pleural or pericardial effusion, † or with satellite tumor nodules within the ipsilateral, primary tumor lobe of the lung. N0 No demonstrable metastasis to regional lymph nodes. N1 Metastasis to lymph nodes in the peribronchial or the ipsilateral hilar region, or both, including direct extension. bronchial biopsy via a fiberoptic bronchoscope, thoracosopic or video-assisted thoracoscopic surgery (VATS), mediastinoscopy, and endoscopic ultrasound with or without biopsy (see Table 3 ). The particular approach in a given patient is determined by the patient's clinical situation and the institutional practices of the treating physician.
Reports established the usefulness of CT-guided biopsy in the past decade [13, 14] , which, during that period, methodological issues, such as optimal bore size of the biopsy needle, were compared [15]; but recently no additional noteworthy additions to that literature have been made. The significant relative disadvantage of the transthoracic needle biopsy is the propensity of pneumothorax to occur as a procedural complication, occurring in approximately 10% to 30% of patients. Pneumothorax is more likely to occur in patients with COPD, who then are also the patient group most disproportionately likely to have lung neoplasia.
Transbronchial needle biopsy via fiberoptic bronchoscopy underwent a similar methdologic evolution [16] [17] [18] [19] [20] . This is the modality for lymph node staging available to the pulmonologist, and has the distinct advantage of being readily tolerable to the patient and able to be performed as part of the original bronchoscopic procedure frequently done to obtain tissue from the primary lesion.
The risk of pneumothorax is negligible, but the diagnostic sensitivity is variable and dependent on operator experience, ranging from 45% to 89% reported in the literature. The availability of an on site cytopathogist's evaluation also increases the yield of this procedure [21] . Noteworthy recent developments involve the use of chest CT to guide lymph node sampling, either with The TNM subsets are combined in sever stage groups, in addition to stage 0, that reflect fairly precise levels of disease progression and their implications for treatment selection and prognosis. Staging is not relevant for occult carcinoma, TX N0 M0. Stage 0 is assigned to patients with carcinoma in situ, which is consistent with the staging of all other sites. Stage IA includes only patients with tumors 3 cm or less in greatest dimension and no evidence of metastasis, the anatomic subset T1 N0 M0. Stage IB includes only patients with a T2 primary tumor classification and no evidence of metastasis, the anatomic subset T2 N0 M0. Stage IIA is reserved for patients with a T1 primary tumor classification and metastasis limited to the intrapulmonary, including hilar, lymph nodes, the anatomic subset T1 N1 M0. Stage IIB includes two anatomic subsets: patients with a T2 primary tumor classification and metastasis limited to the ipsilateral intrapulmonary, including hilar, lymph nodes, the anatomic subset T2 N1 M0; and patients with a primary tumor classification of T3 and no evidence of metastasis, the anatomic subset T3 N0 M0. Stage IIIA includes four anatomic subsets that reflect the implications of ipsilateral, limited, extrapulmonary extension of the lung cancer. , both of which increase the diagnostic yield of the procedure compared to the conventional procedure. Another exciting technology undergoing development is bronchoscopic ultrasound-guided biopsy by which a bronchoscopist can more accurately target and sample lymph nodes before biopsy or with real-time imaging [24, 25] .
Mediastinoscopy remains the gold standard for assessing disease involvement of the mediastinum [26] [27] [28] [29] [30] [31] . Most efforts to validate the utility of other mediastinal staging methods endeavor to save the patient from a surgical procedure with its concomitant expense and morbidity, when the patient could be served as well with staging from a non-invasive or less invasive modality. The fact remains a significant number of patients even with small, peripheral T1 lesions can be found on mediastinoscopy to have metastatic disease in mediastinal lymph nodes [32] , which may be the underlying reason that patients with Stage I disease still have only an average 50 to 60% survival at 5 years. The surgical literature suggests that more extensive mediastinoscopy can be more accurate than conventional mediastinoscopy [33] . While controversy exists about the necessity of mediastinoscopy in the setting of a normal PET scan of the mediastinum, the rationale for routine mediastinoscopy prior to thoractomy for resection is still justifiable [34] . Patients with a potentially resectable lesion but with a positive PET scan of the mediastinum still warrant a tissue diagnosis to confirm malignant involvement because a significant number, approximately 20%, of PET scans with increased metabolic uptake can be a false positive for indicating malignancy for the reason that inflammation and infection can also cause increased uptake [35] . A reasonable goal in the staging workup is to spare a patient a mediastinoscopy if possible, but mediastinoscopy will continue to have an important, irreplaceable role in lung cancer staging.
Endoscopic ultrasound guided biopsy is another relatively new means of invasive, but well-tolerated means of lymph node sampling, by which mediastinal lymph nodes can be visualized and sampled in real-time through an endoscope fitted with an ultrasound transducer placed in the esophagus. Certain nodal locations which are inaccessible to bronchoscopy, such as the aortopulmonary window, which otherwise would require anterior mediastinoscopy (Chamberlain procedure) are readily accessed via endoscopic ultrasound [36] [37] [38] [39] [40] [41] [42] [43] . At the present, endoscopic ultrasound for mediastinal staging of lung cancer is performed at only a few centers, but as the procedure is more widely known and more endoscopists are trained in the procedure, it can be expected to be practiced more extensively in the general medical community.
Positron Emission Tomography (PET) scanning represents the most recent significant innovation in the practice of lung cancer staging. PET is based on the principle that malignant cells have a higher rate of metabolic activity, which is reflected by a more avid uptake of glucose into the cells. Radiolabeled 18 F-fluoro-deoxy-Dglucose (FDG) is taken up by the malignant cells, then trapped intracellularly after phosphorylation. The increased uptake of isotope can then be visualized with a PET camera. As mentioned before, granulomatous, inflammatory, and infectious diseases can also demonstrate positive PET imaging. A lower limit of size for accurate resolution has previously been described at 1.0 to 1.2 cm node size [44] but more recent data published show good detection of malignancy with lymph nodes smaller than one centimeter [45] .
A profusion of recent articles support the role of PET scanning in mediastinal staging [46-65] Some slight difference exists in the test characteristics based on analysis of the entire patient or with individual lymph nodal stations of the unit of analysis, but these distinctions are minor compared to the dramatic improvement in accuracy of PET in comparison to commuted tomography. Summary statistics with the patient as the unit of analysis yielded a sensitivity of 85% (95% CI 0.79-0.89) and a specificity of 88% (95% CI 0.82-0.92). PET is expected to assume an increasingly important role in lung cancer staging, especially as the technology becomes more widespread. In terms of one of the overall goals of staging, i.e. to assess prognosis, PET has shown to be significantly more accurate than CT in predicting survival [66] . PET is most helpful when the mediastinum is negative; in this case, mediastinoscopy may be omitted prior to thoracotomy and tumor resection. In the case with a positive PET with lymph nodes greater than 1 cm, mediastinoscopy or lymph node sampling is obligatory for the reason of false positive scans due to nonneoplastic diseases.
The SPECT scan uses similar principles and technology to assess neoplastic involvement of mediastinal lymph nodes, but clinical practice has proven the PET scan to be useful for the application of lymph node staging [67] . With the PET scan so clearly in the ascendant, little attention is now paid to SPECT in the lung cancer literature.
M (Metastasis) Status Assessment
Extrathoracic involvement of lung cancer is responsible for a substantial portion of the morbidity and mortality associated with this disease. Due to the often insidious nature of lung cancer while confined to the chest, a significant number of patients will present with metastatic disease, or symptoms related to metastatic involvement brings the patient to medical attention. Presence or ab-sence of metastatic disease is the single most important component of the TNM system for predicting survival.
Patients with metastatic disease have no meaningful change for survival, with 5-year survival less than 5%. M1 disease, indicating presence of metastasis, regardless of T or N stage, is designated stage IV.
The organs most frequently involved in lung cancer metastasis are the adrenal glands, brain, bone, and liver. Extrathoracic staging directs particular attention to these potential sites of metastasis, in regard to clinical assessment, imaging modalities, and tissue sampling. In the case of small cell lung cancer, because of the high likelihood of metastatic disease at presentation, search for extrathoracic disease is obligatory, with or without clinical symptoms referable to those locations. CNS imaging and bone scan should be performed sequentially, preferably with head commuted tomography or MRI done first since the CNS is the most common site for metastasis and extensive disease is defined as extrathoracic involvement at one or any site [68]. CNS involvement would establish an extensive disease stage and eliminate the need for a bone scan, since treatment in chemotherapy alone regardless of whether bone metastasis are present as well.
The appropriate evaluation for metastatic disease in a patient with non-small cell lung cancer, as established by evolving consensus, should be more selective and directed based on patient's symptoms and clinical evaluation. As can be understood and forgiven in retrospect, in the early days of computed tomography the recommendation was made that every patient with lung cancer should have imaging of the adrenals, CNS, and liver [69, 70] . The contemporary recommendation is that "the clinician should only search for metastatic disease if they have a compelling reason to do so" [71] . This approach has been substantiated by the bulk of the clinical literature and meta-analysis [72] . For those patients requiring evaluation of a particular implicated organ with metastatic involvement, CT or the chest with cuts through the liver and adrenals, MRI with contrast of the brain [73], and Tc-99 nuclear imaging of the skeletal system [74] are the best imaging modalities for each respective organ. The PET scan, apart from its merits for mediastinal staging as elaborated previously, is recognized to be a useful and accurate test for detecting local and distant metastases as well [75, 76] . While the same standard that metastatic disease should be sought out when clinically warranted, since a PET scan is a whole-body scan, obtaining a PET scan to assess the mediastinum accomplishes the fringe benefit of a reliable assessment of local and distant metastatic disease except for the brain.
Molecular Markers
Analysis of serum molecular markers is an interesting and potentially valuable means of cancer staging undergoing development, but which is not yet ready for com-mon clinical application. Several promising studies have been reported in the last year. Examination of vascular endothelial growth factor (VEGF) from serum or lymph node specimens has been shown to predict survival [77] [78] [79] [80] . Similar study of markers to predict tumor biological behavior include p53 [81] HER2 [82] epidermal growth factor receptor and periostin [83] also have show promise in initial reports. To the clinician these data may not be of practical value, except for affording the appreciation that further progress in characterizing the molecular biology of lung cancer at present appears to be the avenue of research that will have meaningfully significant impact on the evaluation of prognosis and development of more effective treatment.
Practice Guidelines
A helpful innovation for clinicians is the existence and continual updating of practice guidelines for lung cancer staging. Practice guidelines are developed by professional societies and organizations, increasingly based on evidence-based medicine rather than consensus expert opinion, and extend to all aspects of clinical care including diagnosis and management of lung cancer, and for many other areas of medical practice. 
Conclusions
Accurate staging is essential in guiding the treatment of patients with lung cancer. The various methods available for staging and considerations involved in selecting the most appropriate modalities for a given clinical situation have been addressed in this article. Perhaps the most fundamental issue involved is determining which patients are eligible for potentially curative surgical resection, and those with disease spread such that only chemotherapy, radiotherapy, or both, would be of benefit, but with an inherently significant lower likelihood of long-term survival. Patients should be approached with a presumption for the possibility of surgical cure, and that possibility must be entertained until a definitive staging evaluation would prove otherwise, since that determination has a direct bearing on the patient's survival. 
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